Document Classification

Section Type: RESULTS

Text: After an average follow-up of 5. 2 years, lovastatin reduced the incidence of first acute major coronary events (1 83 vs 116 first events ; relative risk [RR], 0. 63 ; 95 % confidence interval [CI], 0. 50-0. 79 ; P <. 001), myocardial infarction (95 vs 57 myocardial infarctions ; RR, 0. 60 ; 95 % CI, 0. 43-0. 83 ; P =. 002), unstable angina (87 vs 60 first unstable angina events ; RR, 0. 68 ; 95 % CI, 0. 49-0. 95 ; P =. 02), coronary revascularization procedures (157 vs 106 procedures ; RR, 0. 67 ; 95 % CI, 0. 52-0. 85 ; P =. 001), coronary events (215 vs 163 coronary events ; RR, 0. 75 ; 95 % CI, 0. 61-0. 92 ; P =. 006), and cardiovascular events (255 vs 194 cardiovascular events ; RR, 0. 75 ; 95 % CI, 0. 62-0. 91 ; P =. 003).